Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ACTRN12626000155392) titled 'A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of subcutaneous NAV-242 in Healthy Adults' on Feb. 6.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Parallel
Type of endpoint: Safety/efficacy
Primary Sponsor: Navigator Medicines
Condition:
autoimmune disease
autoimmune disease
Inflammatory and Immune System - Autoimmune diseases
Skin - Dermatological conditions
Intervention:
This is a Phase 1 study to evaluate the safety, tolerability, PK, PD, and immunogenicity of NAV-242 in hea...